NEWS | upstart

OUR NEWS

XableCath Receives Second FDA Clearance for Its Peripheral Arterial Catheters

SALT LAKE CITY -- (BUSINESS WIRE) -- XableCath, Inc., innovators of products designed to aid in the treatment of peripheral artery...

Q Therapeutics Announces Joint Venture with REPROCELL

Q Therapeutics, Inc., a developer of clinical-stage cell therapies for central nervous system (CNS) diseases, and REPROCELL Inc., Japan’s fi

XableCath Receives FDA Clearance for Broadly Effective Catheter Aimed at Peripheral Arterial Disease

XableCath, a clinical stage medical device company, announced its XableCath blunt tip support catheter has received clearance from the...

Q Therapeutics Announces Research Collaboration With REPROCELL

SALT LAKE CITY and YOKOHAMA, Japan, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage cell therapies...

Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth Launched Exclusively by LabCorp

LabCorp® (NYSE: LH) today announced the nationwide availability of the PreTRM® test. Developed by Sera Prognostics, Inc., the PreTRM test...

IN THE MEDIA

XABLECATH FEATURED IN MEDTECH STRATEGIST AS A STARTUP TO WATCH IN 2018

Salt Lake City, UT – May 11, 2018 – UpStart portfolio company Xablecath offering peripheral vascular interventional tech- nologies appears in the "START-UPS TO WATCH" section of the May edition of MedTech Strategist.

SERA PROGNOSTICS IS NAMED A 2017 SILVER EDISON AWARD WINNER

New York, NY – April 21, 2017 – The Edison Awards, celebrating 30 years of honoring the best in innovation and excellence in the development of new products and services, announced today that Sera Prognostics’ PreTRM Test was voted a Silver Winner for innovation in the “Health and Wellness” category at the April 20th event at The Capitale in New York City.